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BACKGROUND
Induction of delta aminolevulinic acid synthase 1 (ALAS1) gene expression and accu-
mulation of neurotoxic intermediates result in neurovisceral attacks and disease 
manifestations in patients with acute intermittent porphyria, a rare inherited disease 
of heme biosynthesis. Givosiran is an investigational RNA interference therapeutic 
agent that inhibits hepatic ALAS1 synthesis.
METHODS
We conducted a phase 1 trial of givosiran in patients with acute intermittent porphyria. In 
part A of the trial, patients without recent porphyria attacks (i.e., no attacks in the 6 months 
before baseline) were randomly assigned to receive a single subcutaneous injection of one 
of five ascending doses of givosiran (0.035, 0.10, 0.35, 1.0, or 2.5 mg per kilogram of body 
weight) or placebo. In part B, patients without recent attacks were randomly assigned to 
receive once-monthly injections of one of two doses of givosiran (0.35 or 1.0 mg per kilo-
gram) or placebo (total of two injections 28 days apart). In part C, patients who had recur-
rent attacks were randomly assigned to receive injections of one of two doses of givosiran 
(2.5 or 5.0 mg per kilogram) or placebo once monthly (total of four injections) or once 
quarterly (total of two injections) during a 12-week period, starting on day 0. Safety, phar-
macokinetic, pharmacodynamic, and exploratory efficacy outcomes were evaluated.
RESULTS
A total of 23 patients in parts A and B and 17 patients in part C underwent randomiza-
tion. Common adverse events included nasopharyngitis, abdominal pain, and diarrhea. 
Serious adverse events occurred in 6 patients who received givosiran in parts A through 
C combined. In part C, all 6 patients who were assigned to receive once-monthly injec-
tions of givosiran had sustained reductions in ALAS1 messenger RNA (mRNA), delta 
aminolevulinic acid, and porphobilinogen levels to near normal. These reductions were 
associated with a 79% lower mean annualized attack rate than that observed with 
placebo (exploratory efficacy end point).
CONCLUSIONS
Once-monthly injections of givosiran in patients who had recurrent porphyria attacks 
resulted in mainly low-grade adverse events, reductions in induced ALAS1 mRNA levels, 
nearly normalized levels of the neurotoxic intermediates delta aminolevulinic acid and 
porphobilinogen, and a lower attack rate than that observed with placebo. (Funded by 
Alnylam Pharmaceuticals; ClinicalTrials.gov number, NCT02452372.)
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Acute hepatic porphyrias are rare, serious, and life-threatening genetic dis-eases caused by mutations in hepatic heme 
biosynthesis enzymes.1-5 The neurotoxic heme 
intermediates delta aminolevulinic acid (ALA) and 
porphobilinogen (PBG) accumulate in patients 
with acute hepatic porphyrias, leading to acute 
debilitating neurovisceral attacks and, in some 
patients, disabling chronic symptoms.2,3,6-8
The prevalence of mutations among patients 
with acute intermittent porphyria (the most com-
mon subtype of acute hepatic porphyria) is ap-
proximately 1 in 1700 in Western countries,9,10 
although disease penetrance is low, with less than 
10% of patients ever having disease symptoms 
develop.1 Most symptomatic patients have only a 
few attacks in their lifetime; however, approximate-
ly 5 to 8% of symptomatic patients with acute 
intermittent porphyria have recurrent attacks (≥4 
attacks per year), which manifest primarily as 
severe diffuse abdominal pain typically requiring 
urgent medical attention or hospitalization.6,9-11 
No pharmacotherapies for the prevention of at-
tacks are approved, although nontherapeutic mea-
sures, such as trigger avoidance (e.g., porphyrino-
genic drugs and fasting), have proved successful 
in preventing attacks in some patients.11-13 Intra-
venous hemin is approved for the treatment of 
acute attacks and is sometimes used prophylacti-
cally for the prevention of attacks.14-16 However, 
hemin has a short duration of action, requires 
venous access (often through an indwelling ve-
nous catheter), and can have associated side ef-
fects (e.g., infusion-site reactions and headache); 
long-term administration may lead to iron over-
load, venous scarring, and catheter-related infec-
tion.14,16 In refractory cases, liver transplantation 
has been performed; gene therapy is currently in 
early stages of research.17-19
Givosiran is an investigational RNA interfer-
ence therapeutic agent intended to specifically 
lower hepatic delta aminolevulinic acid synthase 1 
(ALAS1) messenger RNA (mRNA) levels, thereby 
decreasing neurotoxic ALA and PBG accumulation. 
Nonclinical studies of givosiran in rodent models 
of acute hepatic porphyria have shown dose-depen-
dent reductions in ALAS1 mRNA, ALA, and PBG 
levels, suggesting a potential therapeutic effect.20
In the current trial, we evaluated the safety, 
pharmacokinetic, and pharmacodynamic profiles 
of givosiran in patients with mutation-confirmed 
acute intermittent porphyria who had elevated 
urinary ALA and PBG levels but did not have 
recent attacks and in those who had recurrent 
attacks. Exploratory analyses were performed to 
evaluate the effect of givosiran on rates of por-
phyria attacks and hemin use among the pa-
tients who had recurrent attacks.
Me thods
Trial Design and Oversight
This multicenter, randomized, placebo-controlled, 
phase 1 trial involving patients with acute inter-
mittent porphyria was conducted in three parts. 
Part A (single injection of an ascending dose) 
and part B (multiple injections of an ascending 
dose) were single-blind trials involving patients 
who had elevated urinary ALA and PBG levels 
but did not have recent attacks (defined as hav-
ing no attacks in the 6 months before baseline); 
these patients were designated as having chronic 
high excretion. Part C (multiple injections) was a 
double-blind trial involving patients who had 
recurrent attacks. Patients were recruited from 
specialist porphyria centers.
The trial was sponsored by Alnylam Pharma-
ceuticals and was designed through a collaboration 
among the sponsor, the principal investigators, and 
porphyria disease specialists. The trial was ap-
proved by central and local institutional review 
boards or ethics committees and was conducted 
in accordance with the principles of the Interna-
tional Conference on Harmonisation Good Clini-
cal Practice guidelines, the World Health Orga-
nization Declaration of Helsinki, and the 1996 
Health Insurance Portability and Accountability 
Act. All patients provided written informed con-
sent. A safety review committee conducted peri-
odic assessments. Data were collected by trial 
investigators and staff and were analyzed by the 
sponsor. Sponsor-employed authors prepared the 
first draft of the manuscript with editorial assis-
tance provided by Adelphi Communications, un-
der contract with Alnylam Pharmaceuticals. All the 
authors interpreted the data, collaborated in pre-
paring the manuscript, and vouch for the accuracy 
and completeness of the data and for the fidelity of 
the trial to the protocol, available with the full text 
of this article at NEJM.org. All the authors, their 
institutions, and the sponsor were required to 
maintain data confidentiality during the trial.
Trial Patients
Eligible patients were men and women 18 to 65 
years of age who had received a diagnosis of acute 
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intermittent porphyria and had a confirmed patho-
genic mutation in the hydroxymethylbilane syn-
thase (also known as PBG deaminase) gene 
(HMBS). Patients were eligible for parts A and B if 
they had a urinary PBG level greater than 4 mmol 
per mole of creatinine (roughly two times the 
upper limit of the normal range) at screening 
and no attacks in the 6 months before baseline.21 
Patients with recurrent attacks (defined as ≥2 at-
tacks within 6 months before the run-in period 
or receiving scheduled hemin prophylaxis at the 
start of the run-in period) were eligible for part 
C. Patients who had been receiving scheduled 
hemin prophylaxis were eligible to participate if 
they were willing to discontinue the treatment 
during the run-in and intervention periods (full 
eligibility criteria are provided in the protocol).
Randomization and Trial Regimen
In part A, patients with chronic high excretion 
were randomly assigned, in a 3:1 ratio, to receive 
a single subcutaneous injection of one of five 
ascending doses of givosiran (0.035, 0.10, 0.35, 
1.0, or 2.5 mg per kilogram of body weight) or 
placebo. In part B, patients with chronic high 
excretion were randomly assigned, in a 3:1 ratio, 
to receive once-monthly injections of one of two 
doses of givosiran (0.35 or 1.0 mg per kilogram) 
or placebo (total of two injections 28 days apart). 
Patients were followed for 42 days after the sin-
gle injection (part A) or 70 days after the first 
injection (part B) or until urinary ALA or PBG 
levels returned to within 80% of the baseline 
value, whichever occurred first; if the levels had 
not returned to at least 80% of the baseline value 
by days 42 or 70, the patients were followed for 
1.5 years or until the ALA or PBG levels returned 
to within 80% of the baseline value. If the levels 
had not returned to within 80% of the baseline 
value by 1.5 years, patients were allowed to com-
plete their end-of-trial visit at the discretion of the 
investigator.
In part C, patients were followed during a 
run-in period (4 to 24 weeks) and were required 
to have had at least one attack before randomiza-
tion. The patients were randomly assigned, in a 
3:1 ratio, to receive injections of one of two doses 
of givosiran (2.5 or 5.0 mg per kilogram) or 
placebo once monthly (total of four injections) 
or once quarterly (total of two injections) during 
a 12-week period, starting on day 0. The patients 
were followed for an additional 12 weeks after 
the last injection. Investigators managed attacks 
according to the local standard of care, which 
could include use of intravenous hemin.
Safety Assessments and Outcome Measures
Safety assessments included monitoring of adverse 
events, clinical laboratory assessments, vital signs, 
12-lead electrocardiography, and physical exami-
nation. Attacks were identified with the use of 
adverse-event data from case-report forms and 
were excluded from the summary tables of ad-
verse events and serious adverse events. All adverse 
events were categorized according to the Medical 
Dictionary for Regulatory Activities, version 17.1, and 
graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events, 
version 4.0.
Pharmacodynamic monitoring included mea-
surements of urinary ALA and PBG levels and the 
circulating hepatic ALAS1 mRNA level. Urinary 
ALA and PBG levels (measured as millimoles per 
mole of urinary creatinine) were determined with 
the use of the ALA/PBG test (Bio-Rad). ALAS1 
mRNA levels were measured with the use of a 
circulating extracellular RNA detection assay of 
exosomes isolated from both serum and urine as 
previously described.22,23 Noncompartmental phar-
macokinetic measurements were calculated from 
plasma and urine samples with the use of Phoe-
nix WinNonlin software, version 7.0 or higher 
(Certara USA).
In part C, the effect of givosiran on rates of 
porphyria attacks and hemin use were explor-
atory end points. Attacks were defined as those 
leading to hospitalization, urgent health care 
visits, or the use of intravenous hemin at home.
Statistical Analysis
Sample size was not determined on the basis of 
power calculations. The safety analysis population 
included all patients in parts A, B, and C who 
had received at least one injection of givosiran or 
placebo. The pharmacokinetic-analysis and phar-
macodynamic-analysis populations included all 
patients who had received at least one injection 
of givosiran or placebo and, for the pharmacoki-
netic-analysis population, had at least one blood 
sample that could be evaluated or, for pharmaco-
dynamic-analysis population, had at least one 
blood or urine sample that could be evaluated. 
In each trial part, data from the patients who 
received placebo were combined across cohorts 
for analysis. Statistical analyses were performed 
with the use of SAS software, version 9.4 or 
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higher (SAS Institute). Descriptive statistics are 
reported for continuous variables, and frequen-
cies and percentages for categorical and ordinal 
variables. Event count data (numbers of por-
phyria attacks and doses of hemin administered) 
are summarized as annualized rates with the 
standard errors of the mean. A negative bino-
mial regression was fitted to generate statistical 
inferences on the ratio of annualized attack rate 
and the annualized number of hemin doses ad-
ministered in each cohort in part C.
R esult s
Trial Population
The randomization and follow-up of patients are 
summarized in Figure S1 in the Supplementary 
Appendix, available at NEJM.org. Enrollment of 
patients began on May 6, 2015, and 4 patients 
were enrolled before the trial was registered at 
ClinicalTrials.gov (May 22, 2015) owing to a mis-
understanding of the required timing for trial reg-
istration. A total of 23 patients with chronic high 
excretion underwent randomization in parts A and 
B (20 were assigned to receive givosiran and 5 to 
receive placebo; 3 patients participated in both 
parts A and B, and 2 patients in part A received 
two injections [either one placebo and one givo-
siran injection or two givosiran injections at differ-
ent doses]). A total of 17 patients with acute inter-
mittent porphyria who had recurrent attacks 
underwent randomization in part C (13 were as-
signed to receive givosiran and 4 to receive pla-
cebo). The baseline demographic and clinical 
characteristics of the patients are shown in Table 1, 
and specific HMBS mutations in the patients are 
summarized in Table S1 in the Supplementary 
Appendix. Part C comprised patients who had 
received as-needed or prophylactic hemin treat-
ment before the start of the run-in period; conse-
quently, there was a range in the reported an-
nualized attack rate before randomization. The 
baseline demographic and clinical characteristics 
of the patients with porphyria disease were gen-
erally balanced between the placebo group and 
the combined givosiran groups in part C (Table 1).
Safety Outcomes
The most common adverse events across trial 
parts A through C were abdominal pain, nausea, 
diarrhea, and nasopharyngitis (Table 2). In parts 
A and B, all adverse events were mild to moder-
ate in severity, and the proportions of patients 
(those who received givosiran and those who 
received placebo) who reported adverse events 
and serious adverse events in each cohort were 
similar; no patient discontinued the trial regimen.
In part A, a serious adverse event of abdomi-
nal pain occurred in two patients who received 
givosiran (one in the 0.035-mg-per-kilogram co-
hort and one in the 1.0-mg-per-kilogram cohort) 
(Table S2 in the Supplementary Appendix). In 
part B, there was a serious adverse event of spon-
taneous abortion in a patient at 7 weeks after 
conception (90 days after the last givosiran dose 
of 1.0 mg per kilogram) (see the Supplementary 
Appendix).
In part C, the 4 patients (100%) who received 
placebo and the 13 patients (100%) who received 
at least two injections of givosiran had an ad-
verse event. Most were mild to moderate in sever-
ity, and the proportion of patients who had a 
severe adverse event was similar in the placebo 
group and the combined givosiran groups (Table 
S3 in the Supplementary Appendix). Injection-site 
reactions were the only adverse events reported 
in more than 2 patients (3 patients [23%]); all 
were mild to moderate in severity and resolved 
spontaneously. No clinically significant changes 
in laboratory measures or in findings from 
physical examinations were noted.
A total of five serious adverse events were 
reported in three patients who received givosiran 
in part C (Table S2 in the Supplementary Appen-
dix). In two patients, the adverse events (influ-
enza A infection and opioid-induced bowel dys-
function) resolved with treatment. The other three 
serious adverse events (Staphylococcus epidermidis 
bacteremia, auditory hallucination, and hemor-
rhagic pancreatitis, which was subsequently fa-
tal) occurred in a single patient who received 
once-monthly injections of givosiran (5.0 mg per 
kilogram). This patient had a complex medical 
history (obesity, hypertension, bacteremia, and 
quadriparesis from acute intermittent porphyria) 
and a clinical course that had been complicated 
by a delay in treatment and hospital admission 
and complications from an acute pulmonary 
thromboembolism that resulted in right heart 
failure (see the Supplementary Appendix). The 
patient was found to have gallbladder sludge on 
ultrasonographic imaging at the time of presen-
tation. Subsequent monitoring of other patients 
did not show any clinically meaningful eleva-
tions in lipase levels during this trial (see the 
Supplementary Appendix).
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Antibodies to givosiran did not develop in 
any of the patients during the trial. Two patients 
had positive antidrug antibody results before the 
administration of givosiran; the antidrug anti-
body levels did not increase during the trial.
Pharmacokinetic and Pharmacodynamic 
Measurements
Pharmacokinetic profiles showed dose-propor-
tional characteristics for givosiran (Fig. S2 and 
Table S4 in the Supplementary Appendix). The 
maximum serum concentration and area-under-
the-curve values were similar after the first and 
second injections of givosiran (either 0.35 or 1.0 mg 
per kilogram [part B]), indicating no drug accu-
mulation with repeated injections (additional 
pharmacokinetic data are provided in the Supple-
mentary Appendix).
Baseline ALAS1 mRNA levels were higher than 
normal by a factor of 2 in patients with chronic 
high excretion and by a factor of 3 to 4 in those 
with recurrent attacks (Table 1, and Fig. S3 in 
the Supplementary Appendix). In part A, a single 
2.5-mg-per-kilogram dose of givosiran led to a 
rapid, dose-dependent reduction from baseline 
in the urinary ALAS1 mRNA level (mean [±SE] 
maximum reduction, 86±8%) (Fig. 1A). The re-
duction in the ALAS1 mRNA level with a single 
2.5-mg-per-kilogram dose led to rapid, dose-
dependent reduction from baseline in the uri-
nary ALA level (Fig. 1B) and PBG level (Fig. 1C) 
(maximum reductions, 91±3% and 96±1%, re-
spectively). In part A, the reduction in the ALAS1 
mRNA level was highly correlated with the uri-
nary ALA level (Pearson correlation coefficient, 
0.79; P<0.001) and PBG level (Pearson correlation 
coefficient, 0.80; P<0.001). Urinary ALA level was 
also highly correlated with PBG level (Pearson 
correlation coefficient, 0.84; P<0.001).
In part B, reductions in the ALAS1 mRNA, 
Characteristic
Parts A and B 
Combined 
(N = 23) Part C
Patients Who 
Received Givosiran 
(N = 13)
Patients Who 
Received Placebo 
(N = 4)
Median age (range) — yr 47 (30–64) 36 (21–59) 42 (27–60)
Female sex — no. (%) 18 (78) 13 (100) 2 (50)
Body weight — kg 75.9±15.9 70.9±14.5 91.4±20.8
Race — no. (%)†
White 22 (96) 10 (77)  4 (100)
Asian 1 (4) 1 (8) 0
Black 0 2 (15) 0
Previous therapy for porphyria — no. (%) NA
Hemin prophylaxis 6 (46) 2 (50)
GnRH analogue 4 (31) 0
Long-term opioid use 7 (54) 2 (50)
Median no. of porphyria attacks in the past 12 mo (range) NA 9 (0–36) 10 (5–50)
Urinary ALA level — mmol/mole of creatinine‡ 23.1±3.1 37.8±6.5 43.1±9.8
Urinary PBG level — mmol/mole of creatinine‡ 24.8±3.6 38.9±5.8 39.2±4.6
Urinary ALAS1 mRNA level — factor change relative to normal 1.9±0.2 4.0±0.5 2.9±0.4
*  Plus–minus values are means ±SD (for body weight) or ±SE (for urinary delta aminolevulinic acid [ALA], porphobilino-
gen [PBG], and ALA synthase 1 [ALAS1] mRNA levels). Hypothesis testing was not performed for the baseline compari-
sons owing to the small sample size involved. Givosiran and placebo group data are not displayed separately for parts 
A and B because they represent the same patient population and the efficacy evaluations were only performed among 
the patients who had recurrent attacks. GnRH denotes gonadotropin-releasing hormone analogue, mRNA messenger 
RNA, and NA not applicable.
†  Race was reported by the patients.
‡  The upper limit of the normal range was 3.8 mmol per mole of creatinine for urinary ALA level and 1.5 mmol per mole 
of creatinine for urinary PBG level.24
Table 1. Demographic and Clinical Characteristics of the Patients with Acute Intermittent Porphyria at Baseline.*
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ALA, and PBG levels similar to those in part A 
occurred after the patients received two once-
monthly injections of givosiran (0.35 or 1.0 mg 
per kilogram) (Fig. S4 in the Supplementary Ap-
pendix). The ALAS1 mRNA, ALA, and PBG levels 
in the patients in both dose cohorts were still 
below baseline at day 70.
In part C, among the patients who had recur-
rent attacks, two once-quarterly injections of 
givosiran resulted in maximum reductions in 
ALAS1 mRNA level of 49±3% in the 2.5-mg-per-
kilogram cohort and 53±7% in the 5.0-mg-per-
kilogram cohort (Fig. 2A). Among the patients 
who received four once-monthly injections of 
givosiran, the maximum reductions in ALAS1 
mRNA level from baseline were 67±3% in the 
2.5-mg-per-kilogram cohort and 74±6% in the 
5.0-mg-per-kilogram cohort (Fig. 2A). Residual 
ALAS1 mRNA levels after once-monthly injections 
of givosiran were at or above the levels seen in 
healthy persons.22 The reductions in ALAS1 mRNA 
level with givosiran were sustained until the end 
of the trial (day 168); there was no evidence of 
ALAS1 mRNA returning to baseline levels at day 
168 in the two dose cohorts that received once-
monthly injections.
The reduction in ALAS1 mRNA level was ac-
companied by rapid and sustained reductions in 
ALA and PBG levels, with a mean maximum 
reduction from baseline of greater than 90% at 
both once-monthly doses (Fig. 2B and 2C). 
Once-monthly injections of givosiran led to 
greater, sustained reductions in ALA and PBG 
levels and lower peak-to-trough fluctuations than 
once-quarterly injections. Normalization of ALA 
and PBG levels occurred in both once-monthly 
dose cohorts (the upper limit of the normal 
range was 3.8 mmol per mole of creatinine for 
ALA level and 1.5 mmol per mole of creatinine 
for PBG level).
Exploratory End Points
During the intervention period of part C (days 0 to 
168), the mean annualized attack rate among 
the patients who received givosiran was 7.2, as 
compared with 16.7 among the patients who 
received placebo (a 57% difference) (Fig. 3A). The 
mean annualized attack rate was 79% lower 
among the patients who received two once-
monthly injections of givosiran (83% lower among 
those who received the 2.5-mg-per-kilogram dose 
and 75% lower among those who received the 
5.0-mg-per-kilogram dose) than among those who 
received placebo. The mean annualized attack 
rate during the intervention period was also re-
duced by 56% from the run-in period among the 
patients who received givosiran, as compared 
with an 18% reduction among the patients who 
received placebo (Table S5 in the Supplementary 
Appendix). When the percentage reduction in ALA 
level from baseline was divided into five catego-
ries (0% [increase or no reduction], >0 to 25%, 
>25 to 50%, >50 to 75%, and >75%) among all 
patients in part C (those who received placebo or 
Adverse Event*
Patients Who 
Received Givosiran 
(N = 33)†
Patients Who 
Received Placebo 
(N = 10)
no. of patients (%)
Any adverse event 30 (91) 10 (100)
Any serious adverse event‡ 6 (18) 0
Any severe adverse event§ 4 (12) 2 (20)
Most common adverse events¶
Nasopharyngitis 9 (27) 2 (20)
Abdominal pain 8 (24) 1 (10)
Nausea 6 (18) 3 (30)
Diarrhea 4 (12) 1 (10)
Back pain 3 (9) 2 (20)
Fatigue 3 (9) 0
Headache 3 (9) 2 (20)
Injection-site reaction 3 (9) 0
Oropharyngeal pain 3 (9) 0
Rash 3 (9) 0
Vomiting 3 (9) 3 (30)
*  If a given adverse event occurred more than once in a patient, that patient 
was counted only once for that adverse event. Adverse events were graded 
 according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events, version 4.0. Severe adverse events were those of grade 3 or 
higher, and serious adverse events were those that resulted in death, were 
life-threatening, required hospitalization or prolongation of an existing hospi-
talization, resulted in persistent or significant disability or incapacity, or re-
quired an intervention to prevent one of the previous items.
†  Two patients in part A received two injections (either one placebo and one 
 givosiran injection or two givosiran injections at different doses). Three pa-
tients were treated in both part A and part B.
‡  Serious adverse events included abdominal pain (2 patients) and spontane-
ous abortion, influenza A infection, functional gastrointestinal disorder (opioid 
bowel dysfunction), staphylococcal bacteremia, auditory hallucination, and 
hemorrhagic pancreatitis (1 patient each). Further details are provided in 
Table S2 in the Supplementary Appendix.
§  In part B, a severe adverse event occurred in a givosiran-treated patient (elbow 
bursitis). In part C, severe adverse events occurred in three givosiran-treated 
patients (influenza A infection and pain in an extremity [after a fall], functional 
gastrointestinal disorder [opioid bowel dysfunction], staphylococcal bactere-
mia, auditory hallucination, and hemorrhagic pancreatitis) and in two placebo-
treated patients (viral gastroenteritis and diarrhea).
¶  The adverse events listed are those that occurred in more than two patients.
Table 2. Adverse Events That Occurred during the Intervention Period among 
Patients Who Received Givosiran or Placebo (Parts A, B, and C Combined).
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givosiran), an association was seen between low-
ering of ALA level and annualized attack rate 
— the patients who had the greatest reduction 
in ALA level had the lowest annualized attack 
rate (Fig. S5 in the Supplementary Appendix).
The annualized number of hemin doses ad-
ministered among the patients who received givo-
siran during the intervention period was 12.1, as 
compared with 23.4 among the patients who 
received placebo (a 48% difference) (Fig. 3B). 
The annualized number of hemin doses admin-
istered during the intervention period was re-
duced by 64% from the run-in period among the 
patients who received givosiran, as compared 
with a 34% reduction among the patients who 
received placebo (Table S6 in the Supplementary 
Appendix; for patient-level data, see Table S7 in 
the Supplementary Appendix). The patients who 
completed part C were enrolled in an ongoing 
open-label extension study (ClinicalTrials.gov 
number, NCT02949830).
Discussion
In the current trial, treatment with givosiran, an 
RNA interference therapeutic agent that targets 
ALAS1 to reduce ALA and PBG levels, was associ-
ated with mainly mild-to-moderate reversible ad-
verse events in patients with acute intermittent 
porphyria who had recurrent attacks. Once-
monthly treatment with givosiran resulted in sus-
tained reductions in ALAS1 mRNA, ALA, and PBG 
levels to near normal. These reductions were 
accompanied by lower annualized rates of por-
phyria attacks and hemin use than those ob-
served with placebo and those observed during 
the run-in period (exploratory end points).
There was no clear difference in the propor-
tion of patients who reported adverse events and 
severe adverse events between the placebo group 
and the givosiran group, and there was no clear 
relationship between givosiran dose and the inci-
dence of adverse events. The most frequently re-
ported adverse events were characteristic symp-
toms of acute intermittent porphyria1 and were 
observed both among the patients who received 
givosiran and among those who received place-
bo. Injection-site reactions were reported in six 
patients who received givosiran (18%) and in no 
patients who received placebo; all reactions were 
mild to moderate in severity.
One patient had a serious adverse event of 
spontaneous abortion at 7 weeks after concep-
Figure 1. Pharmacodynamic Characteristics of a Single Ascending Dose  
of Givosiran in Patients with Chronic High Excretion (Part A).
Changes are relative to baseline. In part A of the trial, patients with acute 
intermittent porphyria who had elevated urinary levels of delta aminolevu-
linic acid (ALA) and porphobilinogen (PBG) but did not have current attacks 
(who were designated as having chronic high excretion) were randomly as-
signed to receive a single subcutaneous injection of one of five ascending 
doses of givosiran (0.035, 0.10, 0.35, 1.0, or 2.5 mg per kilogram of body 
weight) or placebo (day 0). ALA synthase 1 (ALAS1) messenger RNA (mRNA) 
levels were measured with the use of a circulating extracellular RNA detec-
tion assay of exosomes isolated from urine; the results were normalized to 
levels found in normal healthy persons (Panel A).22,23 Urinary ALA (Panel B) 
and PBG (Panel C) levels were normalized to creatinine concentration. I bars 
indicate standard errors.
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tion (90 days after the last givosiran dose). We 
were unable to determine whether this event was 
a spontaneous abortion independent of treatment 
because the rate of such events is approximately 
20% of all pregnancies,25 and some studies sug-
gest that the frequency of spontaneous abortion 
may be higher among patients with acute inter-
mittent porphyria than among healthy women.26,27 
Preclinical biodistribution studies have shown 
that givosiran is predominantly distributed to 
the liver, with exposure levels in extrahepatic 
tissues so low that they would not be expected 
to result in pharmacodynamic activity. To mini-
mize risks in pregnancy, the use of a highly ef-
fective method of birth control while women are 
taking givosiran is required in all protocols.
One patient with multiple coexisting medical 
complications and a delay in treatment had a fatal 
serious adverse event of hemorrhagic pancreatitis. 
Although the investigator considered that this 
event was unlikely to be related to givosiran be-
cause of the identification of a plausible alterna-
tive cause (gallbladder sludge) and the lack of a 
clear temporal relationship to trial-drug injec-
tions, we cannot rule out a causal relationship. In 
the interests of safety going forward, monthly li-
pase monitoring was initiated, and no other cases 
of pancreatitis or lipase elevations greater than 
three times the upper limit of the normal range 
in the current trial and the ongoing open-label 
extension study have been identified to date.
Circulating ALAS1 mRNA levels confirmed the 
central importance of liver ALAS1 induction in the 
pathophysiology of acute intermittent porphyria, 
and the higher levels observed in patients with 
recurrent attacks than in those without attacks 
showed an association between basal ALAS1 
mRNA levels and disease activity. Greater ALAS1 
induction in patients with recurrent attacks re-
quired once-monthly injections of givosiran to 
attain sustained reductions in the levels of ALAS1 
mRNA (approximately 60% reduction from base-
line) and ALA and PBG (approximately 80% re-
duction from baseline for both) to near normal, 
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Figure 2. Pharmacodynamic Characteristics of Multiple 
Ascending Doses of Givosiran in Patients with Recurrent 
Attacks (Part C).
Changes are relative to baseline. In part C of the trial, 
patients with acute intermittent porphyria who had re-
current attacks were randomly assigned to receive in-
jections of one of two doses of givosiran (2.5 or 5.0 mg 
per kilogram) or placebo once monthly (total of four 
injections) or once quarterly (total of two injections) 
during a 12-week period, starting on day 0. ALAS1 mRNA 
levels were measured with the use of a circulating extra-
cellular RNA detection assay of exosomes isolated from 
serum; the results were normalized to levels found in 
normal healthy persons (Panel A).22,23 Urinary levels of 
ALA (Panel B) and PBG (Panel C) levels were normalized 
to creatinine concentration. I bars indicate standard errors.
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whereas less frequent injections were required in 
patients with chronic high excretion.21,22
It is hypothesized that blocking the heme syn-
thesis pathway could lead to heme deficiency 
and dysfunction associated with defects in other 
enzymes containing heme. However, there is little 
evidence of heme deficiency in the liver of pa-
tients with acute intermittent porphyria, as ex-
emplified by normal microsomal heme content 
and cytochrome P450 isozyme activity in a severe-
ly affected patient who underwent liver transplan-
tation.28 Preclinical research in givosiran-treated 
mice showed that a 75% reduction in the Alas1 
mRNA level (with a residual level of 25%) did 
not decrease cytochrome P450 2E1 activity or 
tryptophan pyrrolase saturation.20 In the current 
trial, patients treated with givosiran in part C 
had residual ALAS1 mRNA levels at or above the 
levels found in normal healthy persons, making 
heme deficiency in the liver unlikely.
Nonclinical and clinical data support the role 
of ALA as the key mediator of disease manifesta-
tions in patients with acute hepatic porphyrias, 
although a contribution from PBG has not been 
fully ruled out.29 In vitro studies have shown that 
ALA induces oxidative stress, inflammation, and 
cell death in multiple cell types and potentially 
binds to γ-aminobutyric acid receptors in the 
central nervous system.30-32 In addition, acute 
symptoms similar to those seen in patients with 
acute intermittent porphyria occur in patients 
with ALA dehydratase deficiency porphyria, heredi-
tary tyrosinemia, and lead poisoning, conditions 
that are associated with increased urinary ALA 
levels but not PBG levels.1,3,29 Data from observa-
tional studies show that higher ALA levels are 
associated with greater disease activity, whereas 
interventions that lower ALA levels (e.g., hemin 
therapy or liver transplantation) result in the 
resolution of acute attacks.19,33,34 In the current 
trial, a graded relationship was observed between 
lowering of the ALA level and reduction in an-
nualized attack rate (an exploratory end point). 
The reduction in attack rate was enhanced with 
once-monthly givosiran injections, as compared 
with once-quarterly injections, owing to more 
sustained reductions in ALAS1 mRNA and ALA 
levels. Whether lowering ALA and PBG levels in a 
sustained manner with givosiran has the poten-
tial to affect chronic porphyria symptoms re-
quires further investigation.
In addition to the reduced attack rate, treat-
ment with givosiran reduced the rate of as-needed 
hemin use (an exploratory end point). Decreas-
ing the number of hemin doses needed to treat 
acute attacks can potentially reduce the burden 
of frequent (often weekly) intravenous infusions 
through a large vein or a chronic indwelling 
catheter and the side effects associated with 
long-term administration.16,34
Study limitations included a short intervention 
period and small numbers of patients. These 
phase 1 results require confirmation in a larger 
study with the other subtypes of acute hepatic 
porphyria and a longer treatment duration.
In this small and short phase 1 trial involving 
patients with acute intermittent porphyria, once-
monthly treatment with givosiran was associated 
with mainly reversible mild-to-moderate adverse 
Figure 3. Effect of Givosiran on Annualized Rates of Porphyria Attacks  
and Hemin Use (Part C).
T bars indicate standard errors.
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events and led to sustained reductions in induced 
ALAS1 mRNA, ALA, and PBG levels. Exploratory 
analyses suggested that these reductions in pa-
tients with acute intermittent porphyria who have 
recurrent attacks were associated with lower rates 
of porphyria attacks and hemin use than those 
observed with placebo.
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